Update shared on29 Aug 2025
Fair value Decreased 38%Despite a sharp upward revision in both revenue growth and net profit margin forecasts for Prothena, the consensus analyst price target has significantly decreased from $24.29 to $15.00.
What's in the News
- Phase 1 ASCENT results for PRX012 in early symptomatic Alzheimer's showed promising amyloid plaque reduction and pharmacokinetics, but higher ARIA-E rates than approved therapies; Prothena will seek partnership to advance PRX012 and its preclinical Ab-TfR antibody.
- Prothena reiterated full-year 2025 net cash burn guidance of $240–$248 million, including significant non-cash expenses and a full valuation allowance for deferred tax assets.
- Birtamimab development discontinued, contributing to an anticipated $96 million (midpoint) reduction in annualized net cash burn.
- Prothena announced an approximate 63% workforce reduction to align costs with remaining pipeline and business development plans; expects $16–$20 million in severance and related expenses.
- Prothena was removed from the S&P Biotechnology Select Industry Index.
Valuation Changes
Summary of Valuation Changes for Prothena
- The Consensus Analyst Price Target has significantly fallen from $24.29 to $15.00.
- The Consensus Revenue Growth forecasts for Prothena has significantly risen from 14.8% per annum to 109.9% per annum.
- The Net Profit Margin for Prothena has significantly risen from 10.54% to 16.25%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.